US 12,472,282 B2
Bioengineered wharton's jelly derived extracellular matrix
Omar Aljitawi, Pittsford, NY (US); Hani Awad, Rochester, NY (US); and Michael Becker, Pittsford, NY (US)
Assigned to University of Rochester, Rochester, NY (US)
Appl. No. 17/043,927
Filed by University of Rochester, Rochester, NY (US)
PCT Filed Mar. 29, 2019, PCT No. PCT/US2019/024768
§ 371(c)(1), (2) Date Sep. 30, 2020,
PCT Pub. No. WO2019/191548, PCT Pub. Date Oct. 3, 2019.
Claims priority of provisional application 62/650,551, filed on Mar. 30, 2018.
Prior Publication US 2021/0121604 A1, Apr. 29, 2021
Int. Cl. A61L 27/38 (2006.01); A61L 27/36 (2006.01); A61L 27/54 (2006.01); A61L 27/56 (2006.01); B33Y 70/00 (2020.01); B33Y 80/00 (2015.01); C12N 5/0789 (2010.01); G01N 33/50 (2006.01)
CPC A61L 27/3604 (2013.01) [A61L 27/3691 (2013.01); A61L 27/3834 (2013.01); A61L 27/3847 (2013.01); A61L 27/54 (2013.01); A61L 27/56 (2013.01); B33Y 70/00 (2014.12); B33Y 80/00 (2014.12); C12N 5/0647 (2013.01); G01N 33/5011 (2013.01); A61L 2300/414 (2013.01); A61L 2430/02 (2013.01); C12N 2503/02 (2013.01); C12N 2533/90 (2013.01)] 13 Claims
 
1. A porous matrix comprising molded homogenized decellularized Wharton's jelly matrix (DWJM) having:
a median pore size between about 200 μm and about 350 μm, and
a pore size distribution that is no more than 50% or 17% of the median pore size.